We are pleased to announce the latest addition to our portfolio: ONtrack Biomedical AG
ONtrack Biomedical AG, a Swiss MedTech startup, aims to improve the quality of life of patients by developing in-vitro diagnostic tests for the early and non-invasive detection and monitoring of cancer.
Its first pipeline product, PROBAN, is a urine test designed to improve prostate cancer screening and thus the eligibility criteria for prostate biopsy. PROBAN aims to reduce the burden on patients and healthcare systems through better-informed decisions for downstream healthcare decisions and the associated cost burden.
PROBAN is under development to select patients with a specific risk of harboring a prostate tumor. The aim is to spare men from performing an unnecessary prostate biopsy due to unspecifically high serum PSA levels and to ensure that those men who actually have a prostate tumor do not miss the opportunity of early detection.
Additionally, PROBAN could serve as a monitoring tool for patients undergoing active surveillance, which could ease the burden of repetitive examinations.
We are delighted to have ONtrack Biomedical AG onboard and look forward to supporting their innovative efforts to improve cancer diagnostics and patient care.
Read more about ONtrack Biomedical AG